Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Events

25 May 2016 - 27 May 2016
06 Jun 2016 - 09 Jun 2016
22 Jun 2016 - 24 Jun 2016

Collaboration for Radiotherapy Microphere Drug Development for the Treatment of Primary and Secondary Liver Cancer

By BiotechDaily International staff writers
Posted on 31 Mar 2014
Print article
Sirtex Medical, Ltd. (Sydney, Australia) and Guerbet, SA (Villepinte, France) are entering into a clinical studies collaboration in primary and secondary (metastatic) liver cancer.

The aim of the collaboration is to examine how Sirtex’s SIR-Spheres microspheres and Guerbet’s Lipiodol Ultra Fluid may be combined or sequenced optimally—and additionally developed—for the treatment of patients with hepatocellular carcinoma, metastatic colorectal cancer, metastatic neuroendocrine tumors, and a variety of other primary and secondary liver cancers.

Sirtex’s chief executive officer, Gilman Wong commented that, “Sirtex’s and Guerbet’s shared vision is that one day, rather than being a terminal disease that patients unfortunately die from, liver cancer may be considered a chronic disease that patients can successfully live with. During my time at Sirtex, I have been fortunate to meet a number of patients who have survived their liver cancer for many years following treatment with SIR-Spheres microspheres. We hope through this clinical studies collaboration to make further gains for the benefit of the patients afflicted by liver cancer. Should the initial collaboration prove fruitful, future collaborations in R&D and marketing between our respective companies may be considered.”

Sirtex’s SIR-Spheres microspheres are utilized in selective internal radiation therapy (SIRT), also known as radioembolization, for the treatment of patients with inoperable liver tumors. SIR-Spheres microspheres have been shown in randomized controlled trials (RCTs) to optimize survival in patients with inoperable liver metastases from primary colorectal cancer. SIR-Spheres microspheres are now being assessed in six international, multicenter RCTs in metastatic colorectal cancer (mCRC) and hepatocellular carcinoma (HCC), which cumulatively will enroll over 2,100 patients. The first of these RCTs, the SIRFLOX study, finished patient enrolment in April 2013 and is expected to report its findings in early 2015.

Guerbet’s Lipiodol Ultra Fluid is used in traditional transarterial chemo-embolization (cTACE) procedures for the treatment of patients with inoperable liver tumors. cTACE has been published in over 100 clinical studies. Recently, cTACE has been established as the standard-of-care for the treatment of patients with intermediate stage HCC by three international clinical consensus guidelines in Europe, Japan, and the United States. These consensus guidelines universally recommend cTACE as the standard-of-care for patients with intermediate stage HCC.

Guerbet’s chief executive officer, Yves L’Epine, said, “We are excited about the potential of combining or sequencing our products to improve the efficacy of interventional radiology procedures in patients with unresectable hepatic tumors. Indeed, while Lipiodol and SIR-Spheres individually are well proven and widely used therapies in their own right, they have never been formally evaluated together or sequentially.”

Guerbet is a pharmaceutical group focused on contrast imaging development, offering of contrast products for X-ray and MRI and for interventional radiology, along with a range of injectors and related medical equipment to provide enhanced diagnosis and treatment of patients.

Related Links:

Sirtex Medical
Guerbet 



Print article

Channels

Genomics/Proteomics

view channel
Image: Follicular helper T-cells (TFH cells, shown in blue) play a crucial role in the maturation of antibody-producing B-cells (shown in green). Activated B-cells give rise germinal centers (shown in red), where mature B-cells proliferate and produce highly specific antibodies against pathogens. Top left: normal germinal center in a mouse tonsil. All others: Germinal centers fail to form when the interaction between ICOS and TBK1 is interrupted (Photo courtesy of Dr. Kok-Fai Kong, La Jolla Institute for Allergy and Immunology).

Molecular Pathway Controlling High-affinity Antibody Production Identified

A molecular pathway has been identified that controls formation of follicular helper T-cells (TFH cells) germinal centers and production of high-affinity antibodies through interaction with the inducible... Read more

Drug Discovery

view channel

Experimental Small-Molecule Anticancer Drug Blocks RAS-binding Domains

The experimental small-molecule anticancer drug rigosertib was shown to block tumor growth by acting as an RAS-mimetic and interacting with the RAS binding domains of RAF kinases, resulting in their inability to bind to RAS, which inhibited the RAS-RAF-MEK pathway. Oncogenic activation of RAS genes due to point mutations... Read more

Biochemistry

view channel
Image: A space-filling model of the anticonvulsant drug carbamazepine (Photo courtesy of Wikimedia Commons).

Wastewater May Contaminate Crops with Potentially Dangerous Pharmaceuticals

Reclaimed wastewater used to irrigate crops is contaminated with pharmaceutical residues that can be detected in the urine of those who consumed such produce. Investigators at the Hebrew University... Read more

Lab Technologies

view channel

Huge Modifiable Biomedical Database to Be Available on the Wikidata Site

Genome researchers are exploiting the power of the open Internet community Wikipedia database to create a comprehensive resource for geneticists, molecular biologists, and other interested life scientists. While efficiency in generating scientific data improves almost daily, applying meaningful relationships between... Read more

Business

view channel

European Biotech Agreement to Promote Antigen-Drug Conjugation Technology

Two European biotech companies have joined forces to exploit and commercialize an innovative, site-specific ADC (antigen-drug conjugate) conjugation technology. ProBioGen (Berlin, Germany), a company specializing in the development and manufacture of complex glycoproteins and Eucodis Bioscience (Vienna, Austria), a... Read more
Copyright © 2000-2016 Globetech Media. All rights reserved.